Education
About Us
Working with TipRanks
Follow Us
Charles River Laboratories Intl (CRL)
NYSE:CRL
CRL Stock Chart & Stats
$193.03
-$0.50(-0.26%)
At close: 4:00 PM EST
$193.03
-$0.50(-0.26%)
Day’s Range― - ―
52-Week Range$91.86 - $199.66
Previous CloseN/A
Volume179.29K
Average Volume (3M)1.00M
Market Cap
$9.59B
Enterprise Value$9.81B
Total Cash (Recent Filing)$207.67M
Total Debt (Recent Filing)$2.63B
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Feb 18, 2026EPS Estimate
2.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.43
Shares Outstanding49,215,470
10 Day Avg. Volume785,460
30 Day Avg. Volume1,001,234
Financial Highlights & Ratios
PEG Ratio-9.41
Price to Book (P/B)2.74
Price to Sales (P/S)2.34
P/FCF Ratio18.91
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue2.44
Enterprise Value/Gross Profit7.56
Enterprise Value/Ebitda19.00
Forecast
1Y Price Target
$192.50Price Target Upside-0.27% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)10.24
Revenue Forecast (FY)$4.01B
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCharles River's third-quarter update featured better-than-expected revenue, adjusted EBIT, and adjusted EPS.
Revenue GrowthAn improving environment and increasing proposal activity suggest it's possible to see net B2B begin to improve, setting CRL on a path to achieve revenue growth.
Strategic ReviewThe strategic review could generate significant value for Charles River Labs.
Bears Say
Bookings DeclineNet DSA bookings declined 2% sequentially and 5% year-over-year due to lighter booking activity for small and midsize biotech clients.
DSA Revenue ChallengesCRL's strategic review update suggests full Mfr. sale is unlikely, and the reality is DSA revenue growth will be challenged in '26, with base case being revenue growth down.
Investor ConcernsInvestors are broadly concerned about 2026 revenue growth.
Charles River Labs News
CRL FAQ
What was Charles River Laboratories Intl’s price range in the past 12 months?
Charles River Laboratories Intl lowest stock price was $91.86 and its highest was $199.66 in the past 12 months.
What is Charles River Laboratories Intl’s market cap?
Charles River Laboratories Intl’s market cap is $9.59B.
When is Charles River Laboratories Intl’s upcoming earnings report date?
Charles River Laboratories Intl’s upcoming earnings report date is Feb 18, 2026 which is in 67 days.
How were Charles River Laboratories Intl’s earnings last quarter?
Charles River Laboratories Intl released its earnings results on Nov 05, 2025. The company reported $2.43 earnings per share for the quarter, beating the consensus estimate of $2.338 by $0.092.
Is Charles River Laboratories Intl overvalued?
According to Wall Street analysts Charles River Laboratories Intl’s price is currently Overvalued.
Does Charles River Laboratories Intl pay dividends?
Charles River Laboratories Intl does not currently pay dividends.
What is Charles River Laboratories Intl’s EPS estimate?
Charles River Laboratories Intl’s EPS estimate is 2.35.
How many shares outstanding does Charles River Laboratories Intl have?
Charles River Laboratories Intl has 49,215,470 shares outstanding.
What happened to Charles River Laboratories Intl’s price movement after its last earnings report?
Charles River Laboratories Intl reported an EPS of $2.43 in its last earnings report, beating expectations of $2.338. Following the earnings report the stock price went down -5.707%.
Which hedge fund is a major shareholder of Charles River Laboratories Intl?
Currently, no hedge funds are holding shares in CRL
Charles River Labs Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$192.50 (-0.27% Downside)
$192.50 (-0.27% Downside)
Blogger Sentiment
Bullish
CRL Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 240.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.1%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.45%
12-Months-Change
Fundamentals
Return on Equity
-2.32%
Trailing 12-Months
Asset Growth
-6.12%
Trailing 12-Months
Company Description
Charles River Laboratories Intl
Charles River Laboratories International, Inc. (CRL) is a leading global provider of laboratory services and products that support the pharmaceutical and biotechnology industries. The company operates through two primary segments: Research Models and Services, and Preclinical Services. CRL offers a wide range of services including drug discovery, safety assessment, and laboratory animal research, as well as providing high-quality research models and related services to help clients in their development processes.
CRL Company Deck
CRL Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture. While there were positive developments such as improvements in biotech funding, strategic portfolio adjustments, and RMS segment growth, these were countered by revenue declines in key segments, a decrease in operating margins, and a drop in earnings per share.View all CRL earnings summariesCRL Revenue Breakdown
20.48% RMS
60.53% DSA
19.00% Manufacturing
CRL Stock 12 Month Forecast
Average Price Target
$192.50
▼(-0.27% Downside)
Technical Analysis
Ownership Overview
1.01% Insiders
33.61% Mutual Funds
22.71% Other Institutional Investors
15.52% Public Companies and
Individual Investors